Prometrium Mechanism and Duration of Action
Prometrium (micronized oral progesterone) works by binding to progesterone receptors to induce progestational effects on target tissues, with peak serum levels achieved 2-4 hours after oral administration and a relatively short half-life requiring daily dosing.
Mechanism of Action
Progesterone exerts its effects through multiple pathways:
Receptor-mediated genomic effects: Progesterone binds to specific progesterone receptors (both nuclear and membrane-associated) to induce progestational changes in target tissues, particularly the endometrium 1, 2.
Anti-estrogenic activity: Beyond its primary receptor binding, progesterone interferes with estrogen binding sites, producing anti-estrogenic effects on the endometrium at doses of 200 mg daily 2.
Additional receptor interactions: The hormone demonstrates anti-androgenic and anti-mineralocorticoid effects through interference with other steroid binding sites 2.
Membrane receptor signaling: Progesterone receptor membrane components (PGRMC1 and PGRMC2) mediate non-genomic progesterone signaling and integrate signals from progesterone, heme, and cytochrome P450 enzymes 3.
Neurosteroid effects: When administered orally, progesterone acts as a neurosteroid directly or through its metabolites, providing beneficial effects on brain function including alleviation of anxiety, depression, and sleep problems 1.
Duration of Action and Pharmacokinetics
The pharmacokinetic profile of oral micronized progesterone shows considerable variability:
Absorption and peak levels: After oral administration of 200 mg micronized progesterone, peak serum concentrations occur at approximately 2-4 hours, with mean peak levels ranging from 9.6 to 13.2 ng/ml for standard formulations 4.
Enhanced absorption with oil vehicle: Micronized progesterone in oil achieves significantly higher peak levels (30.3 ± 7.0 ng/ml) at approximately 2 hours after administration 4.
Interindividual variability: There is considerable variation in absorption between individuals, with maximum serum concentrations ranging from 15.72 to 625.98 ng/ml after a single 300 mg dose, and absorption increasing with age 5.
Short half-life: Due to rapid hepatic metabolism, progesterone has a relatively short biological half-life, necessitating daily administration for sustained therapeutic effects 2, 6.
Clinical dosing regimens: Standard therapeutic regimens include 200-300 mg daily taken at bedtime for 10-14 days per month (for cyclic therapy) or 100-200 mg daily for continuous therapy 6.
Clinical Implications
Important considerations for clinical use:
Timing of administration: Bedtime dosing is recommended to minimize transient drowsiness and dizziness, the primary side effects of oral micronized progesterone 1, 6.
Formulation matters: Micronization significantly enhances bioavailability compared to plain milled progesterone, and oil-based vehicles further improve absorption 4.
Peanut allergy caution: Many micronized progesterone capsule formulations contain peanut oil in excipients and are contraindicated in patients with severe peanut allergies; vaginal gel formulations do not contain peanut oil and can be used as alternatives 7.
Metabolic safety profile: Unlike synthetic progestins, oral micronized progesterone has no detrimental effects on lipid profiles, coagulation factors, or blood pressure 2, 6.